. 2020 Dec 3;132(23):742–761. doi: 10.1007/s00508-020-01781-z

Table 3.

Follow-up assessments in patients with cardiac amyloidosis (modified from the recommendations of the German Cardiac Society [143])

Patient situation	AL amyloidosis			ATTR amyloidosis
Patient situation	Frequency (months)	Assessment	Result	Frequency (months)	Assessment	Result
Receiving specific drug treatment	Every 3 (or after every 2 cycles)	NT-proBNP^a; troponin T or I	Treatment success: >30% decrease; treatment failure, >30% increase; compared to previous result	Every 3‑6	NT-proBNP, troponin T or I	Treatment success: depends on drug^b
Receiving specific drug treatment	Every 6	ECG + Holter monitoring; transthoracic echocardiography including strain measurements; if available: heart CMR including LGE and T1 mapping	–	Every 12	ECG + Holter monitoring; transthoracic echocardiography including strain measurements; if available: heart CMR including LGE and T1 mapping	–
After remission or in stable condition who does not receive specific treatment	Every 6	ECG; NT-proBNP^a; troponin T or I; transthoracic echocardiography including strain measurements	–	Every 6	ECG; NT-proBNP^a; troponin T or I; transthoracic echocardiography including strain measurements	–
	Every 12	ECG + Holter monitoring; heart CMR including LGE and T1 mapping if laboratory tests or echocardiography suggest progression	–	Every 12	ECG + Holter monitoring; heart CMR including LGE and T1 mapping if laboratory tests or echocardiography suggest progression	–

CMR cardiac magnetic resonance imaging, LGE late gadolinium enhancement, ECG electrocardiogram, NT-proBNP N-terminal brain natriuretic peptide

^aAssessment of NT-proBNP performed when patient is in cardiac compensation, some time after cortisone administration, if applicable

^bTafamidis, absence of further NT-proBNP elevations rated as treatment success; patisiran, decrease >30% compared to the last results after 9 and 18 months have been reported [123].